SEC Filing Analysis: Apogee Therapeutics, Inc. (APGE)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Financial Officer conducted a small, pre-planned sale of common stock, representing a negligible fraction of her holdings and the company's market capitalization.
• Market Impact: Negligible. The transaction is too small to influence market sentiment or trading volume.

Company Information

Field	Value
Company	Apogee Therapeutics, Inc.
Ticker Symbol	APGE
CIK	0001974640
Industry	Biological Products (No Diagnostic Substances)

Insider Information

Field	Value
Name	Henderson Jane
CIK	0001422304
Title/Position	Chief Financial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-11
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	1,000
Price Per Share	$60.00
Total Value	$60,000
Shares Owned After	199,871
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$60,000
% of Market Cap	0.0014%
Shares Transacted	1,000
% of Shares Outstanding	0.0022%
Post-Transaction Ownership	199,871 shares (0.43% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $60,000 transaction is insignificant against Apogee's $4.31 billion market capitalization.
• Ownership Concentration: The sale represents less than 0.5% of the CFO's holdings, indicating no significant change in her stake. Her remaining ownership is 0.43% of total shares outstanding.
• Transaction Significance: Based on its minuscule percentage of market cap and shares outstanding, the transaction is considered routine and non-material.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is very small and was executed under a Rule 10b5-1 plan, which decouples the transaction from any immediate insider knowledge. It is likely for personal liquidity or diversification.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is too small to affect trading volume.
• Sentiment Indicator: Neutral. The pre-planned nature and small size of the sale do not signal any change in the insider's outlook on the company.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024. This reduces the informational value of the sale as it was pre-scheduled.